What it's for (Indications)
- Desloratadine is a peripherally-selective H1-antihistamine indicated for the rapid and effective relief of symptoms associated with various allergic conditions.
- These include seasonal allergic rhinitis, characterized by symptoms such as sneezing, rhinorrhea (runny nose), nasal pruritus (itching), ocular pruritus (itchy eyes), tearing, and redness of the eyes.
- It is also approved for the treatment of perennial allergic rhinitis, which presents with similar symptoms but on a year-round basis.
- Furthermore, desloratadine is utilized in the management of chronic idiopathic urticaria (CIU), a condition defined by the recurrent occurrence of hives (urticaria) for at least six weeks without an identifiable cause.
- In CIU, desloratadine helps alleviate pruritus (itching) and reduces the size and number of hives, significantly improving the patient's quality of life.
- Its non-sedating properties make it a preferred choice for long-term management of these chronic allergic manifestations, offering symptom control without significant impairment of daily activities.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of desloratadine varies based on age and formulation. For adults and adolescents 12 years of age and older, the recommended oral dose is 5 mg once daily, taken with or without food. For pediatric patients, specific formulations and dosages are available: children 6 to 11 years of age are typically prescribed 2.5 mg once daily (often as an oral disintegrating tablet or syrup); children 1 to 5 years of age should receive 1.25 mg once daily (syrup); and for infants 6 to 11 months of age, the recommended dose is 1 mg once daily (syrup). Dosage adjustments may be necessary in patients with renal or hepatic impairment due to altered drug clearance. In adults with renal or hepatic impairment, a starting dose of 5 mg every other day may be considered, or as directed by a healthcare professional, to prevent drug accumulation and potential adverse effects. It is crucial to adhere strictly to the prescribed dosage and not to exceed the recommended daily amount, as this does not increase efficacy but may heighten the risk of side effects. The duration of treatment depends on the nature and severity of the allergic symptoms and should be determined by a physician. |
Safety & Warnings
Common Side Effects
- While generally well-tolerated, desloratadine, like all medications, can cause side effects.
- The most commonly reported adverse reactions in adults include headache, fatigue, dry mouth, and pharyngitis.
- In pediatric populations, the side effect profile can differ slightly, with fever, diarrhea, insomnia, and somnolence (drowsiness) being observed more frequently in younger children.
- Less common but reported side effects include nausea, dyspepsia, dysmenorrhea, myalgia, and dizziness.
- Although desloratadine is classified as a non-sedating antihistamine, some individuals, particularly those sensitive to antihistamines or taking higher than recommended doses, may still experience mild sedation or drowsiness.
- Serious adverse reactions are rare but can include hypersensitivity reactions such as rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis.
- Hepatic dysfunction, including elevated liver enzymes and hepatitis, and very rarely seizures, have also been reported post-marketing.
- Patients should be advised to report any persistent or bothersome side effects to their healthcare provider.
- It is important to note that this is not an exhaustive list, and other side effects may occur.
Serious Warnings
- Black Box Warning: Desloratadine does not carry a formal FDA-mandated Black Box Warning. Black Box Warnings are reserved for medications that have serious or life-threatening risks. However, despite the absence of such a warning, several serious safety considerations must be diligently observed during its use. Patients should be cautioned that while desloratadine is generally considered non-sedating, individual responses can vary, and some individuals may experience drowsiness or impaired psychomotor function. Therefore, activities requiring mental alertness, such as driving or operating heavy machinery, should be undertaken with caution until the patient understands how the medication affects them. Furthermore, caution is advised when administering desloratadine to patients with pre-existing renal or hepatic impairment, as dose adjustment may be necessary to prevent accumulation and potential adverse effects. Though rare, post-marketing reports have indicated instances of serious hypersensitivity reactions, including anaphylaxis, and very rare cases of seizures; thus, patients should be advised to seek immediate medical attention if signs of a severe allergic reaction or seizure activity occur. The co-administration of alcohol should be approached cautiously as it may theoretically enhance central nervous system depression. Healthcare providers must ensure comprehensive patient education regarding these potential risks and appropriate management strategies.
- Desloratadine should be used with caution in certain patient populations.
- While generally non-sedating, individual responses can vary, and some patients may experience somnolence.
- Patients should be advised to exercise caution when engaging in activities requiring mental alertness, such as driving or operating machinery, until they know how the medication affects them.
- Concurrent use of alcohol with desloratadine is generally not recommended, as it may potentiate central nervous system (CNS) depressant effects, although desloratadine itself has minimal CNS penetration.
- Patients with pre-existing renal or hepatic impairment require careful consideration, and a lower or less frequent dose may be necessary to avoid drug accumulation and potential toxicity, as desloratadine and its active metabolite are primarily eliminated via these routes.
- The safety and efficacy of desloratadine have not been established in children younger than 6 months of age.
- Caution is also advised in patients with a history of seizures, as very rare cases of seizures have been reported in patients taking desloratadine in post-marketing experience.
- Desloratadine is Pregnancy Category C; therefore, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
- Similarly, desloratadine is excreted in breast milk, and a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
How it Works (Mechanism of Action)
Desloratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It is the major active metabolite of loratadine and exhibits potent antihistaminic effects by binding competitively and selectively to peripheral H1-receptors. This blockade prevents histamine, an endogenous inflammatory mediator, from binding to its receptors, thereby inhibiting the cascade of events that lead to the characteristic symptoms of allergic reactions. Unlike first-generation antihistamines, desloratadine exhibits minimal penetration of the blood-brain barrier, which accounts for its classification as a 'non-sedating' antihistamine, significantly reducing the propensity for central nervous system side effects such as drowsiness and cognitive impairment. In addition to its antihistaminic properties, desloratadine has demonstrated various anti-inflammatory effects in in vitro studies, including inhibition of histamine release from mast cells, inhibition of inflammatory mediator release from human mast cells and basophils, and inhibition of expression of adhesion molecules. These ancillary anti-inflammatory actions may contribute to its efficacy in conditions like chronic idiopathic urticaria, beyond simple H1-receptor blockade. The drug is rapidly absorbed after oral administration, reaching peak plasma concentrations within approximately 3 hours, and has a prolonged half-life, supporting once-daily dosing.